XML 40 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Stock award plan - (Tables)
3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Summary of stock option activity

    

    

    

Weighted-

    

  

Weighted-

average

Aggregate

average

remaining

intrinsic

Number of

exercise

contractual

value(in 

options

price

term

thousands)

 

Outstanding at December 31, 2021

 

10,772,582

$

43.66

 

  

 

  

Granted

 

1,275,830

38.10

 

  

 

  

Exercised

 

(97,188)

25.15

 

  

 

  

Forfeited/Cancelled

 

(199,511)

49.92

 

  

 

  

Outstanding at March 31, 2022

 

11,751,713

$

43.11

 

6.97

years

$

38,075

Vested or Expected to vest at March 31, 2022

 

4,497,327

$

48.04

 

8.54

years

$

2,127

Exercisable at March 31, 2022

 

6,763,376

$

39.44

 

5.79

years

$

35,859

Schedule of assumptions used to estimate fair values of grants made on the date of grant

    

Three months ended

    

March 31, 2022

Risk-free interest rate

 

1.55%

Expected volatility

 

73.56%

Expected term

 

5.5 years

Summary of information on the Company's restricted stock

Restricted Stock Awards and Units

Weighted

Average

Grant

Number of

Date

    

Shares

    

Fair Value

Unvested at December 31, 2021

1,519,831

$

55.43

Granted

 

1,490,190

38.10

Vested

 

(426,470)

51.26

Forfeited

 

(68,570)

48.45

Unvested at March 31, 2022

 

2,514,981

$

46.06

Schedule of share-based compensation expense recorded in the statement of operations

Three Months Ended March 31, 

    

2022

    

2021

Research and development

$

13,034

$

13,725

Selling, general and administrative

 

13,555

 

11,982

Total

$

26,589

$

25,707